Physician profile
Haitham Qader
NPI 1841265253
$1,495.12
in general payments reported to CMS, 2019-2025
30 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $140 · 2021: $126 · 2022: $215 · 2023: $201 · 2024: $285 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.60 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181.32 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $132.51 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.73 | 2022-2024 | |
| Amgen INC. | $98.16 | 2019-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $69.56 | 2019-2025 | Velphoro |
| Horizon Therapeutics Plc | $69.26 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $68.47 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $64.08 | 2021-2022 | |
| Travere Therapeutics, INC. | $63.86 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $53.45 | 2019-2023 | Rayaldee |
| Ultragenyx Pharmaceutical INC. | $52.05 | 2019-2023 | Crysvita |
| Medtronic, INC. | $48.46 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $47.68 | 2022-2023 | Conquest |
| Ardelyx, INC. | $47.30 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $43.33 | 2022-2023 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $43.17 | 2019-2020 | |
| Stryker Corporation | $37.03 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Akebia Therapeutics INC | $36.88 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $28.98 | 2025 | Purified Cortrophin Gel |
| Biotronik INC. | $24.18 | 2022 | |
| Cormedix INC. | $23.88 | 2024 | Defencath |
| Lilly USA, LLC | $21.24 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $20.96 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.39 | 2025 | Yorvipath |
| Alnylam Pharmaceuticals INC. | $20.02 | 2023 | Givlaari |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.91 | 2023 | |
| Argon Medical Devices, INC. | $14.96 | 2023 | Cleaner |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2023 | Gattex |
| Mallinckrodt Enterprises LLC | $14.08 | 2019 | |
| Genzyme Corporation | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haitham Qader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.